Oxalate in Healthy Foods May Fuel Gut Inflammation in IBD Patients

Oxalate, a naturally occurring compound abundant in many celebrated plant foods, may pose a hidden risk for people living with inflammatory bowel disease (IBD). New research published in Cellular and Molecular Gastroenterology and Hepatology identifies a biological mechanism by which oxalate accumulates in the intestinal environment of IBD patients and amplifies existing inflammation — a finding with direct implications for dietary guidance and microbiome-based therapies.

The UNC School of Medicine team, led by Anna Salvador, PhD, examined gene expression, stool oxalate levels, and dietary data in IBD patients and healthy controls, supported by mouse models and cell culture experiments. They found that two key oxalate transporter proteins — SLC26A2 and SLC26A3 — were consistently reduced in intestinal tissue from both ulcerative colitis and Crohn's disease patients, regardless of whether active inflammation was present at the time of sampling. As tissue inflammation intensified, transporter expression dropped further, creating a worsening cycle.

A particularly striking finding involved dietary comparison. Using both validated food questionnaires and a novel DNA metabarcoding technique — the first use of this molecular method in an IBD population — the researchers confirmed that Crohn's patients consumed similar quantities of plant-based foods as healthy controls, yet carried significantly more oxalate in their stool. This points to a fundamental biological difference in oxalate handling, not simply dietary excess.

Animal experiments reinforced the clinical data. Mice fed an oxalate-enriched diet alongside a colitis-inducing agent were 60 percent less likely to survive compared to controls, demonstrating oxalate's capacity to potentiate gut inflammation under vulnerable conditions.

For health-conscious adults and clinicians, the implications are meaningful. IBD patients may benefit from low-oxalate dietary modifications even when consuming otherwise nutritious foods. Microbiome interventions targeting oxalate-degrading bacteria represent a promising therapeutic avenue. Caveats include the observational nature of human data and the translational gap between mouse models and human IBD complexity.